What is Netspot (a radiopharmaceutical)?
Netspot is a radiopharmaceutical used in nuclear medicine for imaging. It is based on the radioactive tracer ^18F-fluciclovine (also written as fluciclovine F 18), which helps clinicians visualize metabolic activity in the body using a PET scan.[1]
What is Netspot used to image?
Netspot is used for PET imaging of certain cancer-related targets, most commonly to help evaluate prostate cancer after initial treatment when doctors are looking for sites of disease recurrence.[1]
How does Netspot work in PET imaging?
Netspot contains a PET-emitting radioisotope (^18F). After injection, the tracer accumulates in tissues in a way that can be detected on PET scans. Doctors interpret the resulting images to see where the radiotracer uptake is higher than background tissue, which may correspond to disease-related activity.[1]
How is Netspot administered and imaged?
Netspot is given by intravenous injection, followed by PET imaging performed after tracer uptake time, according to the imaging protocol used by the treating facility.[1]
What are common patient concerns?
Patients typically ask about:
- Radiation exposure from PET imaging, which is expected because the tracer is radioactive.
- Injection-related effects (generally similar to other IV tracers).
- Scan accuracy and next steps, since imaging results guide further staging, treatment planning, or decisions about additional therapy.[1]
Where does Netspot fit compared with other PET tracers for cancer?
Netspot is one of several PET tracers used in oncology. Its role is closely tied to which cancer type and clinical question (for example, prostate cancer recurrence assessment) the clinician is trying to answer. The specific tracer choice depends on indication, availability, and local practice standards.[1]
Are there alternatives to Netspot?
Clinicians may use other PET radiotracers for related indications depending on the clinical scenario (for example, other tracers used for prostate cancer or other cancers). The best alternative depends on the cancer type and the imaging goal.[1]
Sources
- https://www.ncbi.nlm.nih.gov/books/NBK539851/